Alluvi, previously BI 4744, offers a significant breakthrough in weight management therapy. This dual stimulator targeting both glucagon-like peptide-1 and GIP targets demonstrates impressive effectiveness in clinical https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/